Vaccine protection after blinatumomab for childhood leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study checks how well vaccines you got as a baby still protect you after treatment with blinatumomab for B-cell leukemia or lymphoma. It helps doctors understand if you may need extra vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute lymphoblastic leukemia or lymphoma.
- You were between 1 and 21 years old when diagnosed.
- You got all the usual vaccines given during the first year of life.
- Your leukemia has not come back or resisted treatment (no relapse).
- You have not had a bone marrow transplant or cellular therapy, and you won't need one.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial is studying how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) when it is given after the first phase of treatment. It looks at patient data to understand real-world outcomes.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a combination of two drugs, inotuzumab and blinatumomab, for people with B-cell acute lymphoblastic leukemia (B-ALL). It may be an option for newly diagnosed patients who are older or unable to tolerate standard chemotherapy, or for patients whose leukemia has returned or not responded to treatment.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hear when a new B-Cell Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.